PDF(Pubmed)
Abstract：
UNASSIGNED: The black fungus, mucormycosis, is on the list of lethal complications reported in recent times in COVID patients.
UNASSIGNED: This cross-sectional study included all cases of post-COVID-19 mucormycosis. Patients\' demographics, clinical presentations, and general health information were collected using a pre-designed form.
UNASSIGNED: The study included 171 participants with the mean (SD) age as 49 (10) years with the sex distribution as 71% (122/171) male and 29% (49/122) females. About half of the admitted patients (47%) were known cases of Diabetes Mellitus type II with a median (IQR) Glycosylated Haemoglobin (HbA1c) of 9.1% (7-11.1%). Only 28% (48/171) had received the first COVID vaccination, and 2.9% (5/171) were fully vaccinated with two doses. During COVID-19, 76% (130/171) required hospitalisation for a mean (SD) stay of 11 (6.4) days. Eighty percent of the patients (136/171) received steroids during therapy, while 87% (150/171) and 51% (88/171) received antibiotics and antivirals, respectively. Oxygen was administered to 71% of hospitalised patients (120/171), with 39.1% (47/120) receiving it for more than 7 days. About the development of the first symptoms of mucormycosis (headache, nasal congestion, black crusts in the nose, facial pain, swelling in cheeks and eyes, and loss of vision) after being diagnosed with COVID-19, 16% (28/171) reported it within 7 days, 75% (127/171) between 8 and 30th days and 9% (16/171) after a month. On examination, 20% of mucor patients had hard palate findings, eschars, fistulas, and perforations, 38% had periodontal abscesses, and 5% reported tenderness to percussion.
UNASSIGNED: Generally, oral manifestations involved the palate and included varying degrees of mucosal discolouration, swelling, ulcers, superficial necrotic areas, and bone exposure and necrosis with dark eschars.
UNASSIGNED: This cross-sectional study included all cases of post-COVID-19 mucormycosis. Patients\' demographics, clinical presentations, and general health information were collected using a pre-designed form.
UNASSIGNED: The study included 171 participants with the mean (SD) age as 49 (10) years with the sex distribution as 71% (122/171) male and 29% (49/122) females. About half of the admitted patients (47%) were known cases of Diabetes Mellitus type II with a median (IQR) Glycosylated Haemoglobin (HbA1c) of 9.1% (7-11.1%). Only 28% (48/171) had received the first COVID vaccination, and 2.9% (5/171) were fully vaccinated with two doses. During COVID-19, 76% (130/171) required hospitalisation for a mean (SD) stay of 11 (6.4) days. Eighty percent of the patients (136/171) received steroids during therapy, while 87% (150/171) and 51% (88/171) received antibiotics and antivirals, respectively. Oxygen was administered to 71% of hospitalised patients (120/171), with 39.1% (47/120) receiving it for more than 7 days. About the development of the first symptoms of mucormycosis (headache, nasal congestion, black crusts in the nose, facial pain, swelling in cheeks and eyes, and loss of vision) after being diagnosed with COVID-19, 16% (28/171) reported it within 7 days, 75% (127/171) between 8 and 30th days and 9% (16/171) after a month. On examination, 20% of mucor patients had hard palate findings, eschars, fistulas, and perforations, 38% had periodontal abscesses, and 5% reported tenderness to percussion.
UNASSIGNED: Generally, oral manifestations involved the palate and included varying degrees of mucosal discolouration, swelling, ulcers, superficial necrotic areas, and bone exposure and necrosis with dark eschars.
摘要：
■黑木耳,毛霉菌病,在最近报道的COVID患者的致命并发症清单上。
■这项横断面研究包括所有COVID-19后毛霉菌病病例。患者人口统计学，临床表现,使用预先设计的表格收集一般健康信息。
■该研究包括171名参与者，平均年龄（SD）为49（10）岁，性别分布为71％（122/171）男性和29％（49/122）女性。大约一半的入院患者（47％）是已知的II型糖尿病病例，中位数（IQR）糖化血红蛋白（HbA1c）为9.1％（7-11.1％）。只有28%(48/171)接受了第一次COVID疫苗接种，和2.9％（5/171）完全接种两剂。在COVID-19期间，76%(130/171)的人需要住院治疗，平均住院时间(SD)为11(6.4)天。80%的患者（136/171）在治疗期间接受了类固醇，而87%(150/171)和51%(88/171)接受抗生素和抗病毒药物治疗，分别。71％的住院患者（120/171）接受了氧气治疗，39.1%(47/120)收到超过7天。关于毛霉菌病的第一个症状的发展（头痛，鼻塞,鼻子上有黑色的硬皮,面部疼痛,脸颊和眼睛肿胀，和视力丧失)在被诊断为COVID-19后，16%(28/171)在7天内报告，75%(127/171)在8至30天之间和9%(16/171)在一个月后。在检查中，20%的黏液患者有硬腭发现，eschars,瘘管,和穿孔，38%有牙周脓肿,5%的人报告有敲击压痛。
■一般来说，口腔表现涉及上颚，包括不同程度的粘膜变色，肿胀,溃疡,浅表坏死区，和骨骼暴露和坏死与黑暗的结焦。
■这项横断面研究包括所有COVID-19后毛霉菌病病例。患者人口统计学，临床表现,使用预先设计的表格收集一般健康信息。
■该研究包括171名参与者，平均年龄（SD）为49（10）岁，性别分布为71％（122/171）男性和29％（49/122）女性。大约一半的入院患者（47％）是已知的II型糖尿病病例，中位数（IQR）糖化血红蛋白（HbA1c）为9.1％（7-11.1％）。只有28%(48/171)接受了第一次COVID疫苗接种，和2.9％（5/171）完全接种两剂。在COVID-19期间，76%(130/171)的人需要住院治疗，平均住院时间(SD)为11(6.4)天。80%的患者（136/171）在治疗期间接受了类固醇，而87%(150/171)和51%(88/171)接受抗生素和抗病毒药物治疗，分别。71％的住院患者（120/171）接受了氧气治疗，39.1%(47/120)收到超过7天。关于毛霉菌病的第一个症状的发展（头痛，鼻塞,鼻子上有黑色的硬皮,面部疼痛,脸颊和眼睛肿胀，和视力丧失)在被诊断为COVID-19后，16%(28/171)在7天内报告，75%(127/171)在8至30天之间和9%(16/171)在一个月后。在检查中，20%的黏液患者有硬腭发现，eschars,瘘管,和穿孔，38%有牙周脓肿,5%的人报告有敲击压痛。
■一般来说，口腔表现涉及上颚，包括不同程度的粘膜变色，肿胀,溃疡,浅表坏死区，和骨骼暴露和坏死与黑暗的结焦。
